Zinzino Revenue Q1 Up 59% To $74.69 Million

Zinzino AB  Interim Report First Quarter 2025

Based on SEK 100 = $USD 10.33 (Business For Home editor)

Revenues in the first quarter of 2025 amounted to SEK 723.7 (454.5) million, corresponding to 59% (15%) growth compared to the corresponding period last year.

In local currencies, revenues for the first quarter increased by 60% compared to the corresponding period last year. EBITDA increased to SEK 78.8 (51.7) million and the EBITDA margin amounted to 10.9% (11.4%). During the quarter, the acquisition of Zurvita’s assets with associated distributor and customer database was completed.

The acquisition consolidates Zinzino’s position in North America and adds further growth in the region. In addition, New Zealand was launched as an official market during the quarter. After the end of the quarter, the assets of the US/UK based direct sales company Valentus Global was acquired in order to add increased distribution power in Europe.

January – March 2025

• Total revenue amounted to SEK 723.7 (454.5) million, corresponding to a growth of 59% (15%)
• Gross profit amounted to SEK 223.6 (160.9) million and the gross profit margin was 30.9% (35.4%)
• EBITDA amounted to SEK 78.8 (51.7) million and the EBITDA margin was 10.9% (11.4%)
• Cash flow from operating activities totalled SEK 21.1 (-1.7) million
• Zinzino’s Board of Directors proposes a dividend to shareholders of SEK 4.00 (3.00) per share for the financial year 2024, corresponding to a total of SEK 143.1 (102.7) million

About Zinzino

Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven nutritional supplements are available in more than 100 markets across the world.

Zinzino has acquired all assets in the health and wellness companies Zurvita and Xelliss. The company co-owns the Cypriot olive oil producer Cleanthi Alpha-Olenic LTD, and owns the Swiss biotech skincare brand HANZZ+HEIDII, as well as the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden, with additional offices in Europe, Asia, and Australia. For more information please visit www.zinzino.com